Literature DB >> 19139153

Acetylcholine-stimulated [3H]GABA release from mouse brain synaptosomes is modulated by alpha4beta2 and alpha4alpha5beta2 nicotinic receptor subtypes.

Tristan D McClure-Begley1, Nathan M King, Allan C Collins, Jerry A Stitzel, Jeanne M Wehner, Christopher M Butt.   

Abstract

Nicotinic acetylcholine receptor (nAChR) agonists stimulate the release of GABA from GABAergic nerve terminals, but the nAChR subtypes that mediate this effect have not been elucidated. The studies reported here used synaptosomes derived from the cortex, hippocampus, striatum, and thalamus of wild-type and alpha4-, alpha5-, alpha7-, beta2-, and beta4-null mutant mice to identify nAChR subtypes involved in acetylcholine (ACh)-evoked GABA release. Null mutation of genes encoding the alpha4 or beta2 subunits resulted in complete loss of ACh-stimulated [(3)H]GABA release in all four brain regions. In contrast, alpha5 gene deletion exerted a small but significant decrease in maximal ACh-evoked [(3)H]GABA release in hippocampus and striatum, with a more profound effect in cortex. Acetylcholine-stimulated [(3)H]GABA release from thalamic synaptosomes was not significantly affected by alpha5 gene deletion. No effect was detected in the four brain regions examined in alpha7- or beta4-null mutant mice. Further analysis of ACh-evoked [(3)H]GABA release revealed biphasic concentration-response relationships in the four brain regions examined from all wild-type animals and in alpha5 null mutant mice. Moreover, a selective reduction in the maximum response of the high-affinity component was apparent in alpha5-null mutant mice. The results demonstrate that alpha4beta2-type nAChRs are critical for ACh-stimulated [(3)H]GABA release from all four brain regions examined. In addition, the results suggest that alpha5-containing receptors on GABAergic nerve terminals comprise a fraction of the high ACh-sensitivity component of the concentration-response curve and contribute directly to the ability of nicotinic agonists to evoke GABA release in these regions.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19139153      PMCID: PMC2684932          DOI: 10.1124/mol.108.052274

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  39 in total

1.  Cholinergic modulation of nucleus accumbens medium spiny neurons.

Authors:  Mischa de Rover; Johannes C Lodder; Karel S Kits; Anton N M Schoffelmeer; Arjen B Brussaard
Journal:  Eur J Neurosci       Date:  2002-12       Impact factor: 3.386

2.  Data normalization before statistical analysis: keeping the horse before the cart.

Authors:  A A Hancock; E N Bush; D Stanisic; J J Kyncl; C T Lin
Journal:  Trends Pharmacol Sci       Date:  1988-01       Impact factor: 14.819

3.  Nicotine binding and nicotinic receptor subunit RNA after chronic nicotine treatment.

Authors:  M J Marks; J R Pauly; S D Gross; E S Deneris; I Hermans-Borgmeyer; S F Heinemann; A C Collins
Journal:  J Neurosci       Date:  1992-07       Impact factor: 6.167

4.  Mouse strain-specific nicotinic acetylcholine receptor expression by inhibitory interneurons and astrocytes in the dorsal hippocampus.

Authors:  Lorise C Gahring; Karina Persiyanov; Diane Dunn; Robert Weiss; Erin L Meyer; Scott W Rogers
Journal:  J Comp Neurol       Date:  2004-01-12       Impact factor: 3.215

5.  The beta3 nicotinic receptor subunit: a component of alpha-conotoxin MII-binding nicotinic acetylcholine receptors that modulate dopamine release and related behaviors.

Authors:  Changhai Cui; T K Booker; Roberta S Allen; Sharon R Grady; Paul Whiteaker; Michael J Marks; Outi Salminen; Theresa Tritto; Christopher M Butt; W R Allen; Jerry A Stitzel; J Michael McIntosh; Jim Boulter; Allan C Collins; Stephen F Heinemann
Journal:  J Neurosci       Date:  2003-12-03       Impact factor: 6.167

6.  Characterization of nicotine binding in mouse brain and comparison with the binding of alpha-bungarotoxin and quinuclidinyl benzilate.

Authors:  M J Marks; A C Collins
Journal:  Mol Pharmacol       Date:  1982-11       Impact factor: 4.436

7.  The nicotinic acetylcholine receptor subunit alpha 5 mediates short-term effects of nicotine in vivo.

Authors:  Ramiro Salas; Avi Orr-Urtreger; Ron S Broide; Arthur Beaudet; Richard Paylor; Mariella De Biasi
Journal:  Mol Pharmacol       Date:  2003-05       Impact factor: 4.436

8.  Nicotinic binding in rat brain: autoradiographic comparison of [3H]acetylcholine, [3H]nicotine, and [125I]-alpha-bungarotoxin.

Authors:  P B Clarke; R D Schwartz; S M Paul; C B Pert; A Pert
Journal:  J Neurosci       Date:  1985-05       Impact factor: 6.167

9.  Subunit composition and pharmacology of two classes of striatal presynaptic nicotinic acetylcholine receptors mediating dopamine release in mice.

Authors:  Outi Salminen; Karen L Murphy; J Michael McIntosh; John Drago; Michael J Marks; Allan C Collins; Sharon R Grady
Journal:  Mol Pharmacol       Date:  2004-06       Impact factor: 4.436

10.  Characterization of nicotinic receptor-mediated [3H]dopamine release from synaptosomes prepared from mouse striatum.

Authors:  S Grady; M J Marks; S Wonnacott; A C Collins
Journal:  J Neurochem       Date:  1992-09       Impact factor: 5.372

View more
  37 in total

Review 1.  α6β2* and α4β2* nicotinic acetylcholine receptors as drug targets for Parkinson's disease.

Authors:  Maryka Quik; Susan Wonnacott
Journal:  Pharmacol Rev       Date:  2011-12       Impact factor: 25.468

2.  CHRNB2 promoter region: association with subjective effects to nicotine and gene expression differences.

Authors:  N R Hoft; J A Stitzel; K E Hutchison; M A Ehringer
Journal:  Genes Brain Behav       Date:  2010-11-04       Impact factor: 3.449

3.  The nicotinic acetylcholine receptor alpha5 subunit plays a key role in attention circuitry and accuracy.

Authors:  Craig D C Bailey; Mariella De Biasi; Paul J Fletcher; Evelyn K Lambe
Journal:  J Neurosci       Date:  2010-07-07       Impact factor: 6.167

4.  Acetylcholine receptor (AChR) α5 subunit variant associated with risk for nicotine dependence and lung cancer reduces (α4β2)₂α5 AChR function.

Authors:  Alexander Kuryatov; Wade Berrettini; Jon Lindstrom
Journal:  Mol Pharmacol       Date:  2010-09-29       Impact factor: 4.436

5.  Uncovering hidden variance: pair-wise SNP analysis accounts for additional variance in nicotine dependence.

Authors:  Robert C Culverhouse; Nancy L Saccone; Jerry A Stitzel; Jen C Wang; Joseph H Steinbach; Alison M Goate; Tae-Hwi Schwantes-An; Richard A Grucza; Victoria L Stevens; Laura J Bierut
Journal:  Hum Genet       Date:  2010-11-16       Impact factor: 4.132

Review 6.  Inside-out neuropharmacology of nicotinic drugs.

Authors:  Brandon J Henderson; Henry A Lester
Journal:  Neuropharmacology       Date:  2015-02-04       Impact factor: 5.250

7.  Presynaptic GABAB autoreceptor regulation of nicotinic acetylcholine receptor mediated [(3)H]-GABA release from mouse synaptosomes.

Authors:  Tristan D McClure-Begley; Sharon R Grady; Michael J Marks; Allan C Collins; Jerry A Stitzel
Journal:  Biochem Pharmacol       Date:  2014-06-19       Impact factor: 5.858

8.  Neonatal nicotine exposure increases excitatory synaptic transmission and attenuates nicotine-stimulated GABA release in the adult rat hippocampus.

Authors:  Joanne C Damborsky; William H Griffith; Ursula H Winzer-Serhan
Journal:  Neuropharmacology       Date:  2014-06-17       Impact factor: 5.250

9.  Prenatal nicotine exposure increases GABA signaling and mucin expression in airway epithelium.

Authors:  Xiao Wen Fu; Kelsey Wood; Eliot R Spindel
Journal:  Am J Respir Cell Mol Biol       Date:  2010-05-06       Impact factor: 6.914

Review 10.  Insights into the neurobiology of the nicotinic cholinergic system and nicotine addiction from mice expressing nicotinic receptors harboring gain-of-function mutations.

Authors:  Ryan M Drenan; Henry A Lester
Journal:  Pharmacol Rev       Date:  2012-08-10       Impact factor: 25.468

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.